Imvanex (Jynneos) Monkey pox vaccine

2022: EU buys 110,000 monkey pox vaccines from Bavarian Nordic

In mid-June 2022, Bavarian Nordic announced that it would supply Europe with about 110 thousand doses of its MVA-BN vaccine against monkey pox by the end of summer. The financial terms of the agreement were not disclosed.

In response to the continued increase in the number of cases of monkeypox in Europe, which by mid-June 2022 were reported in different countries of the world, including 20 European countries. The European Health Emergency Preparedness and Response Authority has ordered the provision of 110,000 doses of vaccine to European Union member states.

The European Union buys 110 thousand vaccines against monkey pox from Bavarian Nordic

MVA-BN, or modified Ankara-Bavarian Nordic vaccine, is marketed under the brand name Imvanex in Europe, Jynneos in the United States, and Imvamune in Canada. The drug is a non-replicating smallpox vaccine and the only vaccine approved for use against monkeypox as of June 2022. Originally developed by Bavarian Nordic in collaboration with the U.S. government, the vaccine was approved for smallpox immunization by the European Commission (EC), as well as in Canada and the United States, where the drug was subsequently also expanded for use in monkey smallpox.

{{quote 'We are pleased to conclude an agreement with the European Health Emergency Preparedness and Response Authority on the supply of our vaccine. Thus, helping to increase EU preparedness and improve response during the current outbreak of monkey pox throughout Europe, "said Paul Chaplin, President and CEO of Bavarian Nordic. }} In the ongoing monkey smallpox outbreak, Bavarian Nordic has been supplying its vaccine to several governments, including European ones, but this latest agreement represents an agreed coordinated approach to tackling the problem in the EU.^[1]

Notes